Association of blood pressure and hypertension with the risk of parkinson disease: The national FINRISK study

Hypertension

Volumn 57, Issue 6, 2011, Pages 1094-1100

  Qiu, Chengxuan ^a,b   Hu, Gang ^c   Kivipelto, Miia ^a,b   Laatikainen, Tiina ^b   Antikainen, Riitta ^d   Fratiglioni, Laura ^a   Jousilahti, Pekka ^b   Tuomilehto, Jaakko ^b,e,f,g,h  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^d UNIVERSITY OF OULU   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

blood pressure; hypertension; Parkinson disease; prospective study; sex

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; COFFEE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; EDUCATIONAL STATUS; FEMALE; FINLAND; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SMOKING; STROKE; TEA;

ADULT; AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; FEMALE; FINLAND; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SYSTOLE;

EID: 79956361541     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.171249     Document Type: Article

References (29)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5:525-535. (Pubitemid 44262284)
2. Qiu C, Xu WL, Fratiglioni L. Vascular and psychosocial factors in Alzheimer's disease: epidemiological evidence toward intervention. J Alzheimers Dis. 2010;20:689-697.
3. Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care. 2008;31:2003-2005.
4. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Willett WC, Ascherio A. Obesity and the risk of Parkinson's disease. Am J Epidemiol. 2004;159:547-555. (Pubitemid 38327788)
5. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007;69:1688-1695. (Pubitemid 350287125)
6. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2008;70:1438-1444. (Pubitemid 351521937)
7. Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M. Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci. 2010;293:82-86.
8. Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology. 2006; 67:1955-1959. (Pubitemid 44967370)
9. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care. 2007;30:842-847. (Pubitemid 46562366)
10. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology. 2008;70: 1972-1979.
11. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Männistö S, Sundvall J, Jousilahti P, Salomaa V, Valsta L, Puska P. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol. 2010; 39:504-518.
12. Kastarinen M, Antikainen R, Peltonen M, Laatikainen T, Barengo NC, Jula A, Salomaa V, Jousilahti P, Nissinen A, Vartiainen E, Tuomilehto J. Prevalence, awareness and treatment of hypertension in Finland during 1982-2007. J Hypertens. 2009;27:1552-1559.
13. Weisskopf MG, Knekt P, O'Reilly EJ, Lyytinen J, Reunanen A, Laden F, Altshul L, Ascherio A. Persistent organochlorine pesticides in serum and risk of Parkinson disease. Neurology. 2010;74:1055-1061.
14. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord. 2007;22: 2242-2248.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206-1252. (Pubitemid 37553153)
16. Launer LJ, Hughes T, Yu B, Masaki K, Petrovitch H, Ross GW, White LR. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu-Asia Aging Study. Hypertension. 2010;55:1352-1359.
17. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham Study. Am J Cardiol. 1971;27:335-346.
18. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension. 2008;51:952-959. (Pubitemid 351398967)
19. Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75:1470-1471. (Pubitemid 39279820)
20. Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67:600-606.
21. Louis ED, Benito-León J, Bermejo-Pareja F. Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES). Neuroepidemiology. 2009;33:286-292.
22. Nanhoe-Mahabier W, de Laat KF, Visser JE, Zijlmans J, de Leeuw FE, Bloem BR. Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol. 2009;5:533-541.
23. Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's disease: a postmortem study. Acta Neuropathol. 2003;105:415-419. (Pubitemid 36798836)
24. Papapetropoulos S, Ellul J, Argyriou AA, Talelli P, Chroni E, Papapetropoulos T. The effect of vascular disease on late onset Parkinson's disease. Eur J Neurol. 2004;11:231-235. (Pubitemid 38491096)
25. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, Launer LJ, van Buchem MA, Breteler MM. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165-174.
26. Lopez-Real A, Rey P, Soto-Otero R, Mendez-Alvarez E, Labandeira-Garcia J. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J Neurosci Res. 2005;81:865-873. (Pubitemid 41532152)
27. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Lanciego JL, Labandeira-Garcia JL. Estrogen and angiotensin interaction in the substantia nigra: relevance to postmenopausal Parkinson's disease. Exp Neurol. 2010;224:517-526.
28. Yanes LL, Romero DG, Iliescu R, Zhang H, Davis D, Reckelhoff JF. Postmenopausal hypertension: role of the renin-angiotensin system. Hypertension. 2010;56:359-363.
29. Tohgi H, Utsugisawa K, Yoshimura M, Nagane Y, Mihara M. Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits-4 and-2 messenger RNA expression in postmortem human putamen: implications for susceptibility to parkinsonism. Brain Res. 1998;791: 186-190.